Effects of Cilostazol on VEGF and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease
Effects of Cilostazol on Vascular Endothelial Growth Factor , Inflammatory and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease.
Sponsor: Tungs' Taichung Metroharbour Hospital
Listed as NCT00431249, this PHASE4 trial focuses on Hemodialysis Patients and Peripheral Vascular Disease and remains completed. Sponsored by Tungs' Taichung Metroharbour Hospital, it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Feb 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tungs' Taichung Metroharbour Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.